Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RB1 positive |
| Therapy | Dalpiciclib |
| Indication/Tumor Type | colon cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RB1 positive | colon cancer | sensitive | Dalpiciclib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Dalpiciclib (SHR6390) inhibited CDK4/6-RB pathway activation, leading to growth inhibition in an RB1-positive colon cancer cell line in culture, and tumor regression in a cell line xenograft model (PMID: 30724426). | 30724426 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (30724426) | Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models. | Full reference... |